A Long-term Safety Study of the Pan-histone Deacetylase (HDAC) Inhibitor, PCI-24781, in Subjects With Cancer.
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Abexinostat (Primary)
- Indications Cancer
- Focus Adverse reactions
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Mar 2012 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University; PCYC0405CA).